Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to pioneering the development of exosome-based therapeutics. By leveraging its proprietary engEx™ Platform, Codiak aims to harness the power of nature's intercellular communication system to engineer a new class of medicines known as exosome therapeutics. With a focus on oncology and neurology, Codiak is utilizing its engEx™ Platform to build a robust pipeline of therapeutic candidates.

These candidates have the potential to transform the treatment of a wide range of diseases, offering hope to patients worldwide. At Codiak, their mission is to create a major shift in the development of tomorrow's medicines through scientific ambition, remarkable ingenuity, and a passionate determination to improve patients' lives. They are guided by a dedicated leadership team, board of directors, and scientific advisory board, comprised of some of the brightest minds in the biopharma industry.

Join Codiak BioSciences in their quest to advance engineered exosomes and make precision exosome therapeutics a reality, ultimately improving healthcare outcomes for patients everywhere